Literature DB >> 20465641

Some unusual type 2 reactions in leprosy.

V Ramesh1, Manish Pahwa.   

Abstract

BACKGROUND: Type 2 reactions with lepromatous leprosy (LL) not occurring during multi-drug therapy (MDT) have been reported.
METHODS: Three patients have been described, each representing a prototype, the first presenting as bullous erythema nodosum leprosum (ENL), second with ENL erupting after treatment for co-existing pulmonary tuberculosis and resembling immune reconstitution inflammatory syndrome, and a third patient with recurrent Sweets-syndrome like presentation who had taken incomplete MDT in the past for leprosy. In all, the diagnosis was established by demonstration of acid-fast bacilli (AFB) on slit-skin smears (SSS) and histopathology. RESULTS &
CONCLUSION: The fact that reactions can occur in patients with clinically inapparent LL, who are more likely to present in general hospitals, has been reemphasized to enhance awareness among physicians. First presentation of leprosy as ENL is probably precipitated by common antibiotics taken for other illnesses. Since reactional episodes can occur before, during and after MDT for leprosy and the clinical picture is not specific to any of them, it is important to ascertain the status of anti-leprosy therapy during these episodes and treat them accordingly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465641     DOI: 10.1111/j.1365-4632.2009.04280.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  Beneficial Effect of Minocycline as Additional Treatment to Prednisone for Pustular Erythema Nodosum Leprosum.

Authors:  Hendra Gunawan; Yogi Faldian; Reti Hindritiani
Journal:  Int Med Case Rep J       Date:  2022-05-31

2.  Type 2 leprosy reaction with Sweet's syndrome-like presentation.

Authors:  Francielle Chiavelli Chiaratti; Egon Luiz Rodrigues Daxbacher; Antonielle Borges Faria Neumann; Thiago Jeunon
Journal:  An Bras Dermatol       Date:  2016 May-Jun       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.